))
Leqembi: Five insights on the first fully approved Alzheimer's drug
Manage episode 371292259 series 2793637
Sisällön tarjoaa David E. Williams. David E. Williams tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Leqembi was just approved to treat early stage Alzheimer's. In this solo episode, host David Williams shares five thoughts.
- Leqembi is just different enough from Aduhelm to survive scrutiny
- Patient registry requirement is a good idea
- The delivery system isn't ready
- Health equity will suffer
- Public health and prevention would be money better spent
Host David E. Williams is president of healthcare strategy consulting firm Health Business Group. Produced by Dafna Williams.
190 jaksoa
Jaa
